NCT03030612View on ClinicalTrials.gov

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Interventions
DRUG

ARGX-110

ARGX-110 will be administered intravenously.

DRUG

AZA

AZA will be administered subcutaneously/intravenously.

Trial Locations (7)

Unknown

Marseille

Paris

Pierre-Bénite

Toulouse

Aarau

Bern

Zurich

Sponsors

Lead Sponsor

OncoVerity, Inc.

Collaborators (1)

argenx
All Listed Sponsors
collaborator

argenx

INDUSTRY

collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

OncoVerity, Inc.

INDUSTRY